您好，欢迎来到化工原料网！ [登录] [免费注册]
化工原料网
发布求购
位置：首页 > 产品库 > Choline Fenofibrate
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
Choline Fenofibrate
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
Choline Fenofibrate图片
CAS NO:856676-23-8
包装与价格：
包装价格(元)
10mg电议
50mg电议

产品介绍
非诺贝特胆碱 (ABT-335) 是一种非诺贝酸的胆碱盐，可在胃肠道中释放游离的非诺贝酸。
Cas No.856676-23-8
别名非诺贝特胆碱; ABT-335
化学名2-hydroxy-N,N,N-trimethylethanaminium 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoate
Canonical SMILESCC(C([O-])=O)(OC1=CC=C(C(C2=CC=C(Cl)C=C2)=O)C=C1)C.C[N+](C)(CCO)C
分子式C22H28ClNO5
分子量421.91
溶解度≥ 8.44 mg/mL in DMSO with gentle warming, ≥ 55.8 mg/mL in EtOH with gentle warming, ≥ 106.6 mg/mL in Water
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Choline Fenofibrate (ABT-335) is the choline salt of fenofibric acid under clinical development as a combination therapy with rosuvastatin for the management of dyslipidemia. IC50 value:Target:Several clinical trials have been developed with Choline Fenofibrate on Reverse Cholesterol Transport, Macular Edema and Hypertriglyceridemia.

References:
[1]. Jones PH, Bays HE, Davidson MH et al. Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme. Clin Drug Investig. 2008;28(10):625-34.
[2]. Mohiuddin SM, Pepine CJ, Kelly MT et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study. Am Heart J. 2009 Jan;157(1):195-203.
[3]. Zhu T, Awni WM, Hosmane B et al. ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans. J Clin Pharmacol. 2009 Jan;49(1):63-71.
[4]. Goldberg AC, Bays HE, Ballantyne CM et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am J Cardiol. 2009 Feb 15;103(4):515-22.
[5]. Campbell J, Mohiuddin SM. The role of a new formulation of fenofibric acid in the treatment of mixed dyslipidemia in type 2 diabetes. Drugs Today (Barc). 2010 Oct;46(10):757-64.